News and Events

Doctor with patient. Image credit: Canva

Clinical trial researching drug therapy for multiple myeloma

A clinical trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is researching a combination drug therapy for myeloid malignancies.

Celebrating CCR Careers: Yves Pommier, M.D., Ph.D.

Yves Pommier, M.D., Ph.D., is a molecular pharmacologist who has done pioneering work on the mechanisms of topoisomerase and PARP inhibition as well as on the discovery of novel biomarkers for anticancer drug responses. After 45 years at the NIH, he is announcing his retirement.

Celebrating CCR Careers: Zhengping Zhuang, M.D., Ph.D.

Zhengping Zhuang, M.D., Ph.D., is a world-renowned expert in experimental pathology, cancer genetics and cancer therapeutics. He has contributed to biotechnological advancements, drug development and clinical translation of his work in tumor biology. After 32 years serving the NCI, he has announced his retirement.

Acute myeloid leukemia. Image credit: iStock

Researchers uncover why a leukemia treatment can cause problems with movement and balance

Ara-C, also known as cytarabine, is the most common chemotherapy to cause cerebellar toxicity. Researchers discovered how the treatment leaves certain neurons with double-strand breaks in their DNA.

Clinical trial researching drug therapy for cancers of the female reproductive organs

A clinical trial led by Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, is researching drug therapy for ovarian, endometrial or cervical cancers.

Shioko Kimura, Ph.D., in her CCR lab in 2014.

Celebrating CCR Careers: Shioko Kimura, Ph.D.

Shioko Kimura, Ph.D., is a biochemist who specializes in endocrinology. She studies how certain genes and proteins work in the thyroid gland and the lungs. After almost 40 years at NCI, she has announced her retirement.

Blood from wildtype mice (left) showing blast-like T-ALL cells with characteristic blue nuclear staining; blood from mice in which CHMP5 is deficient in thymocytes (right) showing no evidence of T-ALL cells in the blood.

Protein shown to promote transcription factors that support cancer genes in leukemia

CCR researchers have discovered that the CHMP5 protein promotes transcription factors that initiate and sustain the expression of cancer genes in T-cell acute lymphoblastic leukemia models.

Jim Mitchell in front of a machine and a sign that says X-ray on

Celebrating CCR Careers: James B. Mitchell, Ph.D.

James (Jim) B. Mitchell, Ph.D., is a radiation biologist whose research focuses on evaluation of agents in combination with radiation that either enhance tumor sensitivity or protect normal tissues. After nearly 50 years at the NCI, Mitchell has announced his retirement.

Clinical trial researching T-cell therapy for gastrointestinal cancer

A clinical trial led by Nicholas D. Klemen, M.D., Physician-Scientist Early Investigator in the Surgery Branch, is researching T-cell therapy for gastrointestinal cancer.

In people with VHL disease, HIF protein complexes accumulate and promote tumor growth. By binding to HIF-2α (green portion of the HIF protein complex), belzutifan (purple hexagon) inhibits HIF’s tumor-promoting activity.

Belzutifan works steadily in people with VHL-associated tumors

In a recent clinical trial, belzutifan shows long-lasting benefits for patients with von Hippel-Lindau disease.

Breadcrumb